Trends and Regional Disparities in the Treatment of Echinococcosis in Kazakhstan: A Nationwide Retrospective Study (2017–2024)

2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/healthcare14101304
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Echinococcosis is an infection caused by the Echinococcus Granulosus parasite, mainly affecting the liver and, less commonly, the lungs. Surgical intervention is the main treatment for Echinococcus Granulosus, with various approaches available depending on the cyst characteristics. This study provided a comprehensive assessment of age characteristics, hospitalization length, and regional differences in the surgical treatment of echinococcosis in Kazakhstan. Objectives: To conduct a comparative analysis of regional disparities in surgical management of pulmonary echinococcosis in Kazakhstan and identify organizational factors contributing to the burden of emergency surgeries. Methods: A brief description of the main methods or treatments applied. This can include any relevant preregistration or specimen information. Results: A short summary of the article’s main findings. Conclusions: A final summarizing comment of the main conclusions or interpretations. The abstract should be an objective representation of the article; it must not contain results which are not presented and substantiated in the main text and should not exaggerate the main conclusions. Clinical trial abstracts should include items that the CONSORT group has identified as essential.